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Abstract
Background: During the spring of 2009, a pandemic influenza A (H1N1) virus emerged and spread globally. We 
describe the clinical characteristics and factors associated with the death of patients who were hospitalized with 2009 
H1N1 influenza pneumonia in Shenyang, China, from November to December 2009.
Methods: We carried out a retrospective chart review of 68 patients who were hospitalized with pneumonia and 
confirmed to have 2009 H1N1 virus infection by a real time RT-PCR assay of respiratory specimens.
Results: Of the 68 patients we studied, 30 (44%) were admitted to an intensive care unit and 10 (14.7%) died. The 
median age of patients was 41 years (range, 18-66), and only one patient was over 65 years of age. The male to female 
ratio was 2.78:1 (50:18). Of the 68 patients, 23 (34%) had at least one underlying medical condition, 9 (13%) had a 
cigarette index ≥400 and 22 (32%) were obese. All patients underwent chest radiography on admission and the 
findings were consistent with pneumonia in all cases. All patients were treated with oseltamivir and treatment was 
initiated at a median time of seven days after the onset of illness. The laboratory test results indicated lymphopenia, 
hypoproteinemia and elevated lactic dehydrogenase and C reactive protein levels. Of the 68 patients, 33 (52%) showed 
a reduction in CD4 T cell counts. Of the 58 patients who survived, 31 (53%) had lymphopenia and 27 recovered from 
this condition after five days. Of the 10 patients who died, nine (90%) had lymphopenia and only two patients 
recovered from this condition after five days. Obesity and recovery from lymphopenia after five days were factors 
associated with death, as determined by multivariate logistic-regression analysis (obesity, odds ratio = 23.06; 
lymphocytopenia reversion, odds ration = 28.69).
Conclusions: During the evaluation period in Shenyang, China, 2009 H1N1 influenza caused severe illness requiring 
hospitalization in 68 patients, 10 (14.7%) of which died. Many of these patients were considered healthy adults and few 
were elderly (65 years or older). Obesity and lymphopenia, which was not restored after five days of treatment, were 
factors associated with poor outcomes of 2009 H1N1 influenza infection.
Background
In early April 2009, cases of human infection with 2009
pandemic influenza A (H1N1) virus were identified in the
United States [1,2] and Mexico [3], and the virus then
spread rapidly to other regions of the world [4,5]. On
December 20, 2009, more than 208 countries and over-
seas territories or communities had reported laboratory
confirmed cases of pandemic influenza A (H1N1), and at
least 11,516 deaths had occurred [6]. The first case of
2009 pandemic influenza A (H1N1) virus infection in
China was documented on May 10. From May to Novem-
ber of 2009, the number of reported cases in China was
69,160 [China Centre for Disease Control, CDC]. The
majority of the early cases reported mild, influenza-like
illnesses [7-11], but more severe infections have been
reported as the pandemic spreads and the number of
infected individuals increases. The greatest number of
cases of 2009 H1N1 influenza infection resulting in
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severe clinical presentations and death have been
reported in Mexico and other Western countries. The
fatality rate of hospitalized patients with critical illness
due to 2009 H1N1 influenza was about 10% [12-14] in
United States and Mexico. The clinical features included
fever and respiratory symptoms and death most com-
monly resulted from severe acute respiratory distress
syndrome (ARDS) and refractory hypoxemia [7,15-18].
Obesity, underlying health conditions and delayed
neuraminidase inhibitor treatment were the major risk
factors for a poor outcome of infection [17,18]. However,
the clinical outcomes and risk factors associated with
2009 H1N1 influenza infection in China remain to be
determined and variables that could help clinicians to
identify patients at high risk of infection would be valu-
able. Therefore, this report summarizes the clinical mani-
festations, clinical outcomes and the risk factors
associated with death in hospitalized pneumonia patients
associated with 2009 H1N1 influenza infections in She-
nyang, China, during November to December 2009.
Methods
Patients
We carried out a retrospective chart review of 68 patients
who were hospitalized with pneumonia and 2009 H1N1
influenza infection in the First Affiliated Hospital of
China Medical University from November 4, 2009, to
December 31, 2009. During the 2009 H1N1 influenza epi-
demic, patients in clinics or emergency departments who
presented with an influenza-like illness were tested for
2009 H1N1 influenza virus, and only those patients
whose illness was complicated with pneumonia were
admitted to our department. Patients with mild symp-
toms were isolated for treatment at home. Therefore, in
total 68 patients were treated in our department between
November 4th  and December 31st. We retrospectively
studied these 68 cases without any selection. The First
Affiliated Hospital of China Medical University is a ter-
tiary care center that includes obstetric services, pediatric
wards and oncology wards, and treats immunosup-
pressed patients and HIV-infected patients. It is also a
tertiary referral center for adult patients infected with
2009 H1N1 influenza, as appointed by the national gov-
ernment. However, this hospital is not a tertiary referral
center for children and pregnant women infected with
2009 H1N1 influenza, so no children and pregnant
women were involved in our study. All patients were con-
firmed positive for 2009 H1N1 influenza A by a real-time
reverse-transcriptase-polymerase-chain-reaction assay
on respiratory specimens carried out at the CDC. All
tests used standard CDC-based primers. All patients
underwent chest radiography on admission. The study
was approved by the Ethics Committee of China Medical
University.
Study Design
Medical-chart abstractions were performed by physicians
from the Infectious Diseases Department. They used a
standardized form that included demographic data, sea-
sonal influenza vaccination history for the previous year,
smoking status, underlying medical conditions, clinical
signs and symptoms, selected laboratory tests including
C reactive protein (CRP), white blood cell classification
and count, lactic dehydrogenase (LDH), creatine kinase
(CK), glutamic-oxaloacetic transaminase (AST), glutamic
alanine aminotransferase (ALT), albumin (Alb), CD4,
CD8 and CD3 T cell counts, blood gas analyses, blood or
sputum cultures, radiographic findings, intervals
between symptom onset and initiation of oseltamivir
therapy, treatment course and length of stay. The thresh-
olds for each laboratory test are listed in annex and any
elevation or reduction according to the threshold of nor-
mal was defined as an abnormality. The body mass index
(BMI) (the weight in kilograms divided by the square of
the height in meters) of each patient was calculated.
Patients were defined as overweight if their BMI was 24
to 27.9 and obese if their BMI ≥28 according to the crite-
rion established by the Working Group On Obesity In
China (WGOC) in 2005. Lymphocytopenia was defined
as an absolute lymphocyte count ≤800 cells/μL. A ciga-
rette index abnormality was defined as ≥400. Blood gas
analyses were tested by Nova Biomedical Stat Profile, and
the oxygenation index (PaO2/FiO2) was calculated and
abnormality was defined as values ≤300. Blood cultures
were tested using the BactecTM 9240 System (Becton
and Dickinson Company).
Statistical Analysis
Continuous variables were summarized as the mean val-
ues (±SD). For categorical variables, the percentage of
patients in each category was calculated. Clinical charac-
teristics were compared between subgroups of survivors
and deceased and between patients who were admitted to
an intensive care unit (ICU) and those who were not,
with the use of a non-parametric Mann-Whitney U test,
chi-square test or Fisher's exact test, as appropriate. A P
value of less than 0.05 was considered to indicate statisti-
cal significance. We performed bivariate analysis to com-
pare the clinical characteristics of patients who survived
with those of patients who died. We used multivariate
logistic-regression models to further investigate associa-
tions between illness and mortality. Data with a P value <
0.05 was entered into the multivariate logistic regression
model and data with a P value < 0.1 was kept in the
model. All analyses were carried out with the use of SPSS
software for Windows (release 13.0) (from http://
www.bizinsight.com.cn).Cui et al. BMC Infectious Diseases 2010, 10:145
http://www.biomedcentral.com/1471-2334/10/145
Page 3 of 9
Results
Clinical Characteristics
This report describes the 68 patients hospitalized in the
First Affiliated Hospital of China Medical University with
pneumonia and 2009 H1N1 virus infection from Novem-
ber 4 to December 31, 2009. The median age of the
patients was 41 years (range, 18-66 years). 67 (99%) of
patients were 18-59 years of age with only one (1%)
patient over 65 years of age. The male to female ratio was
2.78:1 (50:18). Of the 68 patients, 23 (34%) had an under-
lying medical condition and five (7%) had at least two
such conditions. These conditions included diabetes, car-
diovascular, hepatic, renal, neurologic and pulmonary
diseases (Table 1). Nine (13%) patients had a cigarette
index ≥400. Height and weight measurements were avail-
able for all 68 patients. 20 (29%) of the patients were over-
weight and 22 (32%) were obese (Table 1). None of the
patients had been vaccinated for seasonal or 2009 H1N1
influenza during the 2008-2009 season (an appointed
population, including doctors, were vaccinated for 2009
H1N1 influenza in October, whereas other members of
the population were vaccinated for after December, 2009,
in Shenyang). Symptoms at presentation included a fever,
cough, difficulty breathing, hemosputum, diarrhea and
myalgia. All patients presented with a fever. A cough was
reported in 60 (88%) patients, breathing difficulties were
reported in 31 (46%) patients, hemosputum in 11 (16%)
patients, diarrhea in 5 (7%) patients and myalgia in 18
(27%) patients. The median duration of symptoms before
hospitalization was seven days (range, 5-20 days).
Diagnostic Findings
Five patients showed baseline chronic abnormalities in
the results of laboratory tests as a result of their underly-
ing medical conditions. Three patients showed a reduced
level of serum Alb of 31, 27 and 24.5 g/L, one patient
showed a mild elevation of ALT at 67 U/L and one
deceased patient showed an elevated level of Cr at 340
μmol/L. The majority of the laboratory test data was
acquired within 48 h of hospital admission, including
CRP, LDH, CK, AST, ALT, Alb, CD4, CD8 and CD3 T cell
count and blood gas analyses. As for white blood cell clas-
sification and counts, there were 59 patients whose sam-
ples were taken in the clinics or emergency rooms of our
hospital and nine patients whose samples were taken in
other hospitals. The median interval from the onset of ill-
ness to the time of sample collection was five days (range,
3-9). Ten patients ultimately died and the median interval
from the time of sample collection to death was seven
days (range, 5-21). The lymphocyte counts for all patients
were monitored every other day until their lymphocyte
counts recovered to normal levels. Laboratory tests
abnormalities included lymphopenia (59%), elevated
serum LDH (84%), CK (37%), AST (56%), ALT (38%) and
CRP (63%). All patients were tested for HIV infection and
were negative. Of the 64 patients, 33 (52%) had reduced
CD4 T cell counts.
Blood cultures were performed for patients who dis-
played a high fever above 38.0°C for at least three days or
patients who had a repeated fever. Sputum cultures were
also performed for patients who showed symptoms of
expectoration especially in cases where the sputum was
yellowish and purulent. All but three patients had
received antibiotics prior to sample collection. Five of 11
patients had positive blood cultures: two of which were
Acinetobacter baumannii, one was methicillin-resistant
Staphylococcus cohnii, one was methicillin-resistant
Staphylococcus saprophyticus and one was methicillin-
resistant Staphylococcus aureus. Nine of 29 patients had
positive sputum cultures: six of which were A. bauman-
nii, two were Pseudomonas aeruginosa and one was
methicillin-resistant S. aureus. All 68 patients who under-
went chest radiography on admission displayed clinical
signs that were consistent with pneumonia. Radiographic
findings included bilateral infiltrates (in 64 patients), an
infiltrate limited to one lobe and multi-lobe infiltrates
limited to one lung. Of 68 patients who underwent blood
gas analysis, 38 (56%) had an oxygenation index below
300.
Treatment
All 68 patients received oseltamivir treatment. The
median time from the onset of illness to the initiation of
antiviral therapy was seven days (range, 2-15). Of 68
patients, 50 (74%) were treated with antiviral therapy
within 48 hours of hospital admission, and 18 (26%) were
treated after 48 hours. All 68 patients received antibiotic
therapy, with 78% of the patients receiving more than one
antibiotic. The median value for the number of antibiot-
ics administered was two (range, 1-7) and the median
duration of antibiotic treatment was seven days. Com-
monly used antibiotics included cefminox and levofloxa-
cin. Of the 68 patients, 66 (97%) received corticosteroids
by means of an injection. The average dosage of methyl-
prednisolone was 1 mg·kg-1·d-1 and the median time for
initiation of methylprednisolone in hospital was day 7. Of
the 68 patients, 48 (71%) received extrasin alpha1.
ICU Admissions
Of the 68 patients we evaluated, 30 (44%) were admitted
to an ICU and 10 of these died. There were no significant
differences in the average age, cigarette index ≥400 and
interval time from the onset of illness to the initiation of
antiviral therapy between patients who were admitted to
an ICU and patients who were not (Table 2). Patients who
were admitted to an ICU were more likely than patients
who were not admitted to an ICU to have an underlying
medical condition and a BMI ≥28 (Table 2). Of the 30Cui et al. BMC Infectious Diseases 2010, 10:145
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patients who were admitted to an ICU, 16 (53%) had at
least one underlying medical condition, including tuber-
culosis (1), asthma (1), chronic obstructive pulmonary
disease (COPD) (1), chronic renal failure (1), chronic
hepatitis B virus infection (1), fatty liver disease (1),
hypertension (7), congenital heart disease (1), rheumatic
heart disease (2), Guillain-Barre syndrome (1) and pitu-
itary adenoma (1). Seven of the 38 (18%) patients who
were not admitted to an ICU had an underlying medical
condition, including tuberculosis (1), COPD (2), liver cir-
rosis (1), diabetes (2), hypertension (2), nephrotic syn-
drome (1) and a kidney transplant (1).
Laboratory test data showed that the levels of serum
LDH and CRP were higher in patients who were admitted
to an ICU than those who were not admitted (P < 0.05)
(Table 2). Patients who were admitted to an ICU also
showed a more significant reduction in serum Alb, lym-
phocyte counts, CD4, CD8 and CD3 T cell counts, com-
pared with patients who were not admitted to an ICU (P
< 0.05) (Table 2). In a multivariable model that included
BMI ≥28, medical conditions, LDH, CRP and CD4 T cell
count, no variable was significantly associated with
admission to an ICU.
Of the 30 patients who were admitted to an ICU, 13
required mechanical ventilation, 8 had acute respiratory
distress syndrome (ARDS), and 21 had a clinical diagno-
sis of sepsis. All patients received antiviral drugs, antibi-
otics, corticosteroids and extrasin alpha1. The median
time from the onset of illness to the initiation of antiviral
therapy was seven days (range, 4-12).
Outcomes
Of the 68 hospitalized patients, 58 (85.3%) were dis-
charged and 10 (14.7%) died. The median time from the
onset of illness to death was 11 days (range, 7-26). The
median time from hospital admission to death was six
days (range, 3-21). The median length of hospital stay for
survivors was 11 days (range, 3-37). There were no signif-
icant differences in median age, cigarette index ≥400 and
Table 2: Comparison between the clinical characteristics and laboratory test abnormalities of patients with pneumonia 
and 2009 H1N1 influenza who were admitted to an ICU and patients who were not admitted to an ICU in the First Affiliated 
Hospital of China Medical University during November 4 to December 31, 2009.
Clinical characteristic or laboratory 
test abnormality
ICU Non-ICU P
data n data n
Medical Condition (no. (%)) 16 (53) 30 7 (18) 38 0.003#
Cigarette index ≥ 400(no. (%)) 5 (17) 30 4 (10) 38 0.458
BMI ≥ 24 (no. (%)) 23(77) 30 19(50) 38 0.025#
BMI 24-27.9 10 (33) 30 10 (32) 38 0.528
BMI ≥ 28 13 (43) 30 9 (24) 38 0.085
Median age 41 (18-63) 30 41 (18-66) 38 0.990
Interval from onset of illness to 
initiation of antiviral therapy, in days
7 (4-12) 30 7 (2-15) 38 0.551
Lymphcyto count (×109/L) 0.58 (0.02-4.34) 30 1.065 (0.31-2.48) 38 <0.0005**
LDH (U/L) 1097.5 (218-4340) 30 688 (180-2250) 37 0.005**
CK (U/L) 220 (23-4188) 30 161 (20-2712) 37 0.313
AST (U/L) 66 (12-229) 30 41.5 (13-339) 38 0.107
ALT (U/L) 45.5 (15-188) 30 43.5 (11-204) 38 0.537
Alb (g/L) 28.95 (18-42) 30 37 (9.6-51) 38 <0.0005**
CRP (mg/mL) 2.66 (0.25-29.7) 27 1.23 (0.1-10.2) 38 0.024**
CD4 T cell count (/μL) 232 (29-1892) 28 651 (128-1607) 36 <0.0005**
CD8 T cell count (/μL) 166.5 (23-1109) 28 406 (85-1113) 36 <0.0005**
CD3 T cell count (/μL) 465 (57-3046) 28 1148.5 (216-2496) 36 <0.0005**
**..... Statistically significant with the use of a non-parametric Mann-Whitney U test; #..... Statistically significant with the use of a chi-square 
test or Fisher's exact test test
BMI: Body Mass Index; LDH: lactic dehydrogenase; CK: creatine kinase; AST: glutamic-oxaloacetic transaminase; ALT: glutamic alanine 
aminotransferase; Alb: albumin; CRP: C reactive protein.Cui et al. BMC Infectious Diseases 2010, 10:145
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interval time from the onset of illness to the initiation of
antiviral therapy, between patients who died and patients
who survived (Table 3). Patients who died were more
l i k e l y  t h a n  p a t i e n t s  w h o  s u r v i v e d  t o  h a v e  u n d e r l y i n g
medical conditions and a BMI value ≥28 (Table 3). Of the
10 patients who died, six had at least one underlying
medical condition, including tuberculosis (1), chronic
renal failure (1), chronic hepatitis B virus infection (1),
asthma (1), COPD (1), hypertension (2) and congenital
heart disease (1). Of the 58 patients who survived, 17 had
an underlying medical condition, including tuberculosis
(1), hypertension (7), rheumatic heart disease (2), Guil-
lain-Barre syndrome (1), fatty liver disease (1), pituitary
adenoma (1), COPD (2), liver cirrosis (1), diabetes (2),
nephrotic syndrome (1) and a kidney transplant (1).
Laboratory test results were compared between
patients who survived and those who died. No differences
were found in the levels of serum CK, AST and ALT
between patients who survived and those who died.
However, patients who died were more likely than
patients who survived to have elevated levels of serum
LDH and CRP and reduced levels of Alb and CD4, CD8
and CD3 T cell counts (P < 0.05) (Table 3). In addition, we
noticed that 40 patients suffered from lymphocytopenia
during the early stage of illness. Among these patients, 31
recovered and nine died. Of the 31 surviving patients, 27
(87%) recovered from lymphocytopenia within five days,
while just two of the patients who later died recovered
from lymphocytopenia within five days (Table 3).
In a multivariate model that included BMI ≥28, medical
conditions, CRP, CD4 T cell counts and lymphocytopenia
reversion, the variables that were significantly associated
with death were BMI ≥28 and delayed lymphocytopenia
recovery (Table 4). All patients who died had received
Table 3: Comparison of the clinical features and laboratory test abnormalities between patients with pneumonia and 
2009 H1N1 influenza who died and those who survived in the First Affiliated Hospital of China Medical University during 
November 4 to December 31, 2009.
Clinical characteristic or laboratory test abnormalities Died Survived P
data n data n
Medical condition (no) 6 10 17 58 0.076
Cigarette index ≥ 400(no) 2 10 7 58 0.611
BMI ≥ 24(no) 9 10 33 58 0.045#
BMI 24-27.9 1 10 19 58 0.260
BMI ≥ 28 8 10 14 58 0.001#
Median age 43.5(24-63) 10 41(18-66) 58 0.562
Interval from onset of illness to initiation of antiviral therapy, in 
days
6(4-10) 10 7(2-15) 58 0.345
Lymphocyte count (×109/L) 0.58(0.02-1.15) 10 0.79(0.31-4.34) 58 0.025**
LDH(U/L) 2583(324-4340) 10 775(180-4104) 57 0.003**
CK(U/L) 299.5(25-2000) 10 165(20-4188) 57 0.268
AST(U/L) 84(16-225) 10 43(12-339) 58 0.091
ALT(U/L) 54(23-167) 10 41.5(11-204) 58 0.446
Alb(g/L) 27.3(18-33) 10 35(9.6-51) 58 0.003**
CRP (mg/mL) 9.515(2.32-27.1) 8 1.49(0.1-29.7) 57 0.001**
CD4 T cell count (/μL) 118.5(29-391) 8 470.5(86-1892) 56 <0.0005**
CD8 T cell count (/μL) 87(23-293) 8 307(44-1113) 56 <0.0005**
CD3 T cell count (/μL) 219(57-697) 8 784(169-3046) 56 <0.0005**
Lymphocyte count ≤ 0.8×109/L (no) 9 10 31 58
Duration of lymphocytopenia 5.5 (4-19) 10 5 (3-9) 58
Duration of lymphocytopenia > 5 days (no) 7 10 4 58
**..... Statistically significant with the use of a non-parametric Mann-Whitney U test; #..... Statistically significant with the use of a chi-square test 
or Fisher's exact test test
BMI: Body Mass Index; LDH: lactic dehydrogenase; CK: creatine kinase; AST: glutamic-oxaloacetic transaminase; ALT: glutamic alanine 
aminotransferase; Alb: albumin; CRP: C reactive protein.Cui et al. BMC Infectious Diseases 2010, 10:145
http://www.biomedcentral.com/1471-2334/10/145
Page 6 of 9
antiviral drugs, antibiotics and corticosteroids. The
median time from the onset of illness to the initiation of
antiviral therapy was six days (range, 4-10).
Discussion
Here, we report on a series of hospitalized patients with
pneumonia caused by 2009 H1N1 influenza infection in
Shenyang, China, from November to December 2009.
During the period of our study, the pandemic strain of
H1N1 virus caused severe illness, including pneumonia
and ARDS, and resulted in ICU admissions in 44% of
patients and death in 14.7% of patients. These findings
were similar to the majority of reports in other countries
[14,17,19,20].
In our study, almost 80% of the hospitalizations due to
H1N1 influenza infection involved individuals who were
between the ages of 18 and 49 years. The male to female
ratio was 2.78:1. These age and sex distributions were dif-
ferent from those reported nationally for the normal pop-
ulation in China (male to female ratio was 106.30:100; age
distributions were: 15-59 years, 68.70%; 60 years and over,
11.03%; 65 years and over, 7.69%). We concluded that
severe illness resulting from H1N1 virus infection was
more likely among male adults in Shenyang, which was
consistent with other reports [19,21-25]. Persons aged 50
years or older showed a low incidence of 2009 H1N1
influenza infection, this may be due to "protection" by
preexisting immunity resulting from previous exposure
to H1N1 influenza infection, along with reduced outdoor
activity by these individuals because of the fear of H1N1
infection. A recent study demonstrated that persons aged
50 years or older who were hospitalized with pandemic
2009 influenza A (H1N1) infection were among those
most likely to die, despite having lower hospitalization
rates [14]. However, our findings did not support this
conclusion, possibly due to the small sample size used in
our study. Nevertheless, it is appropriate that clinicians
should closely monitor elderly patients with pandemic
2009 H1N1 influenza infection and treat them accord-
ingly.
In our study, almost 30% of patients had pre-existing
medical conditions, of which chronic pulmonary dis-
eases, diabetes and hypertension were the most common
diseases, as found in other studies [19,24,25]. The
patients included in our study who died had a higher rate
of pre-existing diseases. Asthma is also considered a high
risk factor for 2009 H1N1 influenza infection, however,
our findings did not confirm this as only one patient in
our study had asthma as a pre-existing condition. This
discrepancy might be caused by the lower morbidity of
asthma in China (approximately 2%) compared with
Western counties (approximately 10-30%). COPD and
heart disease are also considered high risk factors for
2009 H1N1 influenza infection, and in our study about
two thirds of the patients with pre-existing medical con-
ditions suffered from COPD or heart disease. Thus, it is
appropriate that physicians should pay close attention to
patients with COPD or chronic heart disease during the
2009 H1N1 influenza epidemic.
In our study, 32% of patients were obese compared with
7% of adults in the normal population in China, which
indicated severe illness from H1N1 virus infection was
more likely among obese individuals, as reported in other
studies [17,18,24,26,27]. Almost 80% of patients who died
from H1N1 influenza infection were obese and using
multivariate logistic-regression models, obesity was
found to be a factor associated with death from 2009
H1N1 influenza in our study, despite the wide 95% confi-
dence interval (CI) for the odds ratio (OR) for BMI due to
the limitations of using a small sample size.
The clinical features of patients who were hospitalized
with 2009 H1N1 influenza infection included fever,
cough, myalgia and dyspnea, which were generally similar
to other reports. Whereas the incidence of gastrointesti-
nal symptoms such as nausea, vomiting, and diarrhea was
much lower than previously reported [7,15-18,28,29].
The results of laboratory tests indicated lymphopenia,
hypoproteinemia, elevated LDH and CRP levels, which
were consistent with other reports [19,29,30]. Abnormal-
ities in the laboratory test results were more significant in
patients who were admitted to an ICU and/or died than
in patients who were not admitted to an ICU, but these
abnormalities were not predictive factors in ICU admis-
sion or death. Our results were not consistent with the
study in Taiwan which found initial lymphocyte count
less 800/microL was associated with the development of
respiratory failure [31]. Although lymphopenia was not a
risk factor for death in our study, we found lymphopenia
was restored after about five days in most surviving
patients, whereas this was not observed in patients who
ultimately died. The multivariate logistic-regression
model results indicated that lymphopenia that did not
resolve after five days was a risk factor for death. Further-
more, we determined the CD4 and CD8 T cell counts in
most of the patients included in our study. The results
indicated a reduction in CD4 and CD8 T cell counts in
about half of the patients during the early stage of 2009
H1N1 virus infection, which was similar to previous
reports in China [7,32]. These findings indicated that
lymphopenia was mostly caused by T cell reduction, in
particular a reduction in CD4 T cells. We were unable to
determine whether the low immunity was pre-existing or
caused by H1N1 infection because we did not know the
b a s i c  v a l u e s  f o r  e a c h  p a t i e n t .  D u r i n g  t h e  s e v e r e  a c u t e
respiratory syndromes (SARS) epidemic, lymphopenia
was considered to be caused by the virus infection but
further studies are needed to investigate the precise host
immune response to 2009 H1N1 influenza virus. TheseCui et al. BMC Infectious Diseases 2010, 10:145
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results suggest the physicians should pay close attention
to patients who are infected with 2009 H1N1 influenza
virus, who are also obese or have experienced long-term
lymphopenia.
In the 1918-1919 influenza A pandemic, most deaths
were attributed to concurrent bacterial infection [31]. A
report into 2009 pandemic H1N1 influenza also indicated
that 29% of the patients displayed bacterial coinfection,
which might have contributed to the death rate in the
current pandemic [33]. In our study, only 16% patients
had positive blood or sputum cultures, and most of these
pathogens could potentially be responsible ventilator-
associated pneumonia. The majority of bacterial co-
infections were drug-resistant bacteria such as A. bau-
mannii and methicillin-resistant S. aureus, whereas non
drug-resistant bacteria were found predominantly in
other reports [33,34]. This result may reflect the abuse of
antibiotics in China, and Chinese physicians should take
measures to ensure protection against respiratory
machine-related pneumonia, especially involving drug-
resistant bacteria. To achieve this, physicians, nurses and
patients should obey the rules of segregation and steril-
ization strictly and pay attention to bacteria contamina-
tion and the rational use of antibiotics. Few bacterial co-
infections were detected in patients who did not have
mechanical ventilation, which was consistent with most
previous studies [14,26]. However, bacterial diagnostic
tests were not performed for all patients, especially those
who were not admitted to an ICU, and most patients
received antibiotics close to the time of culture collection,
which could have reduced the diagnostic sensitivity.
Although antiviral therapy is most beneficial when
treatment is initiated within 48 hours after the onset of
illness [35], a prospective cohort study of oseltamivir
therapy in patients hospitalized with influenza infection
indicated a reduction in mortality, even when such ther-
apy was initiated more than 48 hours after illness onset
[36]. Recent data from Thailand also showed that oselta-
mivir therapy was associated with survival in hospitalized
patients with influenza pneumonia [37]. Under an Emer-
gency Use Authorization, the FDA recently approved
oseltamivir therapy for 2009 H1N1 infection even if it is
initiated more than 48 hours after the onset of illness and
also approved its use in children under the age of one year
[35]. In our study, antiviral drugs were administered to all
patients, but such therapy was not initiated within 48
hours of the onset of illness in all patients and there was
no difference between surviving patients and those who
died in the median number of days from the onset of ill-
ness to oseltamivir initiation. Therefore, we were unable
to conclude whether or not antiviral therapy in critically
ill patients led to better clinical outcomes. No patients
undertook the test of the isolated 2009 H1N1 influenza A
strains for oseltamivir resistance in our study, so whether
oseltamivir resistance affected the outcomes of patients
with 2009 H1N1 infection was unclear. Delayed initiation
of antiviral therapy may have contributed to an increased
severity of illness in our study.
Our study has several limitations. The patients we eval-
uated represented 30% of the total hospitalizations in
Shenyang for 2009 H1N1 infection that were reported to
the CDC during the surveillance period that ended in
December, 2009. No children or pregnant women were
included in our study. Participation in the study was vol-
untary and was therefore subject to reporting bias. We
evaluated only patients with confirmed 2009 H1N1 infec-
tion, so the group may not be representative of all hospi-
talized patients as some may have gone undetected. All
diagnostic testing was clinically driven, and tests were not
obtained in a standardized fashion. Finally, despite the
use of a standardized data-collection form, not all of the
required information was collected for all of the patients
and the sample size was small.
Conclusions
During the evaluation period in Shenyang, 2009 H1N1
influenza caused severe illness requiring hospitalization.
Thirty percent of the patients need an intensive care unit
and fifteen percent died. Obesity and lymphopenia,
which was not restored after five days of treatment, were
factors associated with poor outcomes of 2009 H1N1
influenza infection. Early identification of pneumonia-
susceptible patients at high risk of 2009 H1N1 influenza
infection may aid clinicians in carrying out effective clini-
cal management of this disease.
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CDC: centre for disease control; CRP: C reactive protein;
LDH: lactic dehydrogenase; CK: creatine kinase; AST:
glutamic-oxaloacetic transaminase; ALT: glutamic ala-
Table 4: Results of multivariate logistic analysis to compare the outcomes of patients who survived with those who died.
variables entered into the model Variables in the equation B S.E. OR P 95% CI
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CD4 T cell counts lymphocytopenia 
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Administration.
Author's information
Wei Cui is an associate professor in-residence in the
Department of Infectious disease, the First affiliated hos-
pital of China Medical University. Her research interests
included the pathogenesis of infectious diseases, particu-
larly the pathogenesis of fulminant hepatic failure and
intestinal barrier disruption.
Appendix
Normal values obtained from laboratory tests in adults:
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